Mizuho Lifts LeonaBio to Outperform, Doubles Price Target on Breast Cancer Asset and Model Reboot
Mizuho upgraded LeonaBio to Outperform from Neutral and increased its price target to $10.00 from $4.00 following a model reboot that introduced first-time forecasts for lasofoxifene in mutated ESR1 metastatic breast cancer and for ATH-1105 in ALS. The firm projects peak global unadjusted sales for lasofoxifene at $1.7 billion and risk-adjusted sal…